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Abstract: In clinical trials of heart failure reduced ejection fraction (HFrEF), ivabradine seemed to be an effective heart rate
lowering agent associated with lower risk of cardiovascular death. In contrast, ivabradine failed to improve cardiovascular
outcomes in heart failure preserved ejection fraction (HFpEF) despite the significant effect on heart rate. This meta-analysis
is the first to compare the effects of ivabradine on heart rate and mortality parameters in HFpEF versus HFrEF. We screened
three databases: PubMed, Embase, and Cochrane Library. The outcomes of these studies were mortality, reduction in heart
rate, and left ventricular function improvement. We compared the efficacy of ivabradine treatment in HFpEF versus HFrEF.
Heart rate analysis of pooled data showed decrease in both HFrEF (–17.646 beats/min) and HFpEF (–11.434 beats/min), and
a tendency to have stronger bradycardic effect in HFrEF (p = 0.094) in randomized clinical trials. Left ventricular ejection
fraction analysis revealed significant improvement in HFrEF (5.936, 95% CI: [4.199–7.672], p < 0.001) when compared with
placebo (p < 0.001). We found that ivabradine significantly improves left ventricular performance in HFrEF, at the same
time it exerts a tendency to have improved bradycardic effect in HFrEF. These disparate effects of ivabradine and the higher
prevalence of non-cardiac comorbidities in HFpEF may explain the observed beneficial effects in HFrEF and the unchanged
outcomes in HFpEF patients after ivabradine treatment.
Key words: heart failure, heart failure preserved ejection fraction, heart failure reduced ejection fraction, ivabradine, heart
rate, left ventricular function.
Résumé : Dans les essais cliniques portant sur l’insuffisance cardiaque à fraction d’éjection réduite (HFrEF), l’ivabradine
semblait constituer un agent efficace pour abaisser la fréquence cardiaque et associé avec une réduction du risque de mort
cardiovasculaire. En revanche, l’ivabradine n’est pas parvenue à entraîner une amélioration des résultats sur le plan cardio-
vasculaire dans l’insuffisance cardiaque à fraction d’éjection préservée (HFpEF), en dépit d’un effet notable sur la fréquence
cardiaque. La présente méta-analyse est la première à présenter une comparaison entre les effets de l’ivabradine sur la fré-
quence cardiaque et les paramètres de la mortalité dans l’HFpEF par rapport à l’HFrEF. Nous avons passé au crible trois
bases de données (PubMed, Embase, Cochrane Library). Les paramètres de l’étude étaient la mortalité, la diminution de la
fréquence cardiaque et l’amélioration de la fonction ventriculaire gauche. Nous avons comparé l’efficacité du traitement
par l’ivabradine dans l’HFpEF par rapport à l’HFrEF. PROSPERO: CRD42019141406. L’analyse de données de fréquence cardia-
que regroupées a montré une diminution dans l’HFrEF (–17,646 battements/min) comme dans l’HFpEF (–11,434 battements/
min), ainsi qu’une tendance vers un effet bradycardisant plus marqué dans l’HFrEF (p = 0.094) dans le cadre d’essais avec
répartition aléatoire. L’étude de la fraction d’éjection ventriculaire gauche a révélé une amélioration marquée dans l’HFrEF
(5,936, IC à 95 % : [4,199–7,672], p < 0,001), ainsi que par rapport au placebo (p < 0,001). Nous avons observé que l’ivabradine
entraîne une amélioration notable de la performance du ventricule gauche dans l’HFrEF, et en même temps une tendance vers
une amélioration de l’effet bradycardisant dans l’HFrEF. Ces effets disparates de l’ivabradine et une augmentation de la fréquence
des comorbidités non cardiaques dans l’HFpEF pourraient expliquer les bienfaits observés dans l’HFrEF de même que les résultats
inchangés après un traitement par l’ivabradine chez les patients atteints d’HFpEF. [Traduit par la Rédaction]
Mots-clés : insuffisance cardiaque, insuffisance cardiaque à fraction d’éjection préservée, insuffisance cardiaque à fraction
d’éjection réduite, ivabradine, fréquence cardiaque, fonction ventriculaire gauche.
Received 1 December 2020. Accepted 1 May 2021.
N. Tóth and A. Orosz. Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School University of Szeged, Dóm Square 12,
Szeged 6720, Hungary.
A. Soós, A. Váradi, P. Hegyi, andM. Solymár. Institute for Translational Medicine, Medical School, University of Pécs, 12 Szigeti Street, Pécs 7624,
Hungary.
B. Tinusz. Institute for Translational Medicine, Medical School, University of Pécs, 12 Szigeti Street, Pécs 7624, Hungary; First Department of Medicine,
Medical School, University of Pécs, Ifjúság Street 13, Pécs 7624, Hungary.
A. Vágvölgyi, A. Polyák, and A.S. Farkas. Department of Internal Medicine, Albert Szent-Györgyi Medical School University of Szeged, Kálvária sgt. 57,
Szeged 6720, Hungary.
A. Varró and N. Nagy. Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School University of Szeged, Dóm Square 12,
Szeged 6720, Hungary; ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary.
Corresponding author: Attila Farkas (email: farkas.attila@med.u-szeged.hu).
© 2021 The Author(s). Permission for reuse (free in most cases) can be obtained from copyright.com.
Can. J. Physiol. Pharmacol. 00: 1–16 (0000) dx.doi.org/10.1139/cjpp-2020-0700 Published at www.cdnsciencepub.com/cjpp on xx xxx xxxx.


























































Chronic heart failure (HF) is a common, complex, and progres-
sive cardiovascular clinical syndrome affecting millions of peo-
ple worldwide, caused by several conditions including coronary
artery disease, myocardial infarction, systemic and pulmonary
hypertension, valvular heart diseases, cardiomyopathies, and con-
genital cardiovascular disorders (Inamdar and Inamdar 2016).These
conditions result in the impairment of left ventricular (LV) filling or
ejection of blood, causing inadequate perfusion and oxygenation
to the tissues (Yancy et al. 2013). HF is always accompanied with
serious structural and electrical remodeling causing myocardial
hypertrophy, fibrosis, and alterations in different cardiac ion chan-
nel protein expression levels (Wang et al. 2010). According to the
impairment of LV function,HF is now classifiedwith preserved ejec-
tion fraction (HFpEF), with mid-range ejection fraction (HFmrEF)
and with reduced ejection fraction (HFrEF) (Ponikowski et al. 2016).
HFrEF is referred to as systolic HF, resulting from the impairment
of LV function, thus reduced ejection of blood, causing ≤40% LV
ejection fraction (LVEF). HFmrEF represents a ‘grey area’ including
patients with LVEF in the range of 40%–49%, characterized by signs
of HF with modest LV systolic dysfunction and with features of
diastolic dysfunction. HFpEF is known as diastolic HF with ≥50%
LVEF, however, recent studies suggest more heterogeneous patho-
physiology including the stiffening of ventricular tissue, atrial dys-
function, ventricular systolic and diastolic reserve abnormalities, or
endothelial dysfunction (Borlaug 2014). In general, all types of HF
are a subject of structural and functional remodeling, however,
these changes may differ in HFrEF versus HFpEF.
Heart rate is a modifiable risk factor with prognostic value in
HF and increased heart rate is associated with increased risk of
cardiovascular mortality and serious life-long cardiovascular dis-
eases (Palatini and Julius 2004; Bohm et al. 2010). The Framing-
ham study demonstrated the association between increased heart
rate and increased cardiovascular risk showing that both the
healthy population and patients withHFwere subjected to a higher
risk in mortality outcomes with increased heart rate (Kannel et al.
1987).
Ivabradine (Procoralan) is a heart rate lowering drug that inhib-
its the pacemaker (“funny”) current (If) (DiFrancesco 1993) and
was first known as an antianginal agent in the treatment of
chronic stable angina pectoris (Borer et al. 2003). In clinical trials
involving HFrEF patients, ivabradine seemed to be a selective and
effective heart rate lowering agent, associated with lower risk of
cardiovascular death and hospital readmissions, emphasizing
that heart rate reduction should be an important target in the
therapy of HF (Swedberg et al. 2010). In clinical conditions, the
European Society of Cardiology (ESC) guidelines recommend
ivabradine treatment to reduce the risk of cardiovascular death
and HF hospitalization in symptomatic patients with LVEF ≤ 35%
in sinus rhythm with resting heart rate at 70 bpm or higher, in
spite of treatment with an evidence-based dose of b-blocker,
angiotensin-converting enzyme inhibitor, or angiotensin recep-
tor blocker (Ponikowski et al. 2016). It should also be considered
in symptomatic patients to whom the b-blockers are contraindi-
cated or not tolerated (Ponikowski et al. 2016). It is important to
note that ivabradine was found to increase the risk of atrial fibril-
lation (Tanboga et al. 2016). In the meta-analysis including eight
randomized clinical trials (RCTs), ivabradine increased the rela-
tive risk of atrial fibrillation by 24% (Tanboga et al. 2016). In a
HFpEF rabbit model, ivabradine was able to reduce cardiac fibro-
sis (Busseuil et al. 2010) and also improved LV systolic and dia-
stolic function in mouse (Reil et al. 2013); however, in human
HFpEF patients, ivabradine also decreased the heart rate, but it
was not associated with improvements in LV relaxation and filling
pressure (Komajda et al. 2017). As ivabradine failed to improve out-
comes in a clinical trial of HFpEF, heart rate reduction with ivabra-
dinemay not be beneficial in HFpEF (Komajda et al. 2017). The exact
reason of different actions and the underlying mechanism is not
understood. Our hypothesis is that the different stages and progres-
sion of electrical remodeling between HFpEF and HFrEF may
explain this discrepancy, however, there is no study directly com-
paring the ivabradine effects between HFpEF and HFrEF thus far.
This meta-analysis is the first to investigate the effect of ivabradine
in HFpEF compared to HFrEF patients focusing on HF hospitaliza-
tion, mortality, and cardiovascular outcome parameters, particu-
larly heart rate reduction and LV function inHFrEF versus HFpEF.
2. Materials and methods
The protocol of this meta-analysis was registered a priori on the
international prospective register of systematic reviews (PROSPERO)
database under CRD42019141406.
2.1. Search
A systematic electronic search was conducted up to 4th of April
2019 in Medline, Embase, and Cochrane Library databases for rel-
evant publications reporting cardiovascular outcomes after ivab-
radine treatment in HF, without any language restrictions or
filters, and was re-conducted at the end of 2020 to avoid omission
of recent publications, though none were found. To perform a
precise search in the databases the following search term was
used: (ivabradine OR procoralan) AND (heart failure OR haemo-
dynamic OR ejection fraction OR heart function OR reduced car-
diac function OR ventricular dysfunction OR cardiac failure OR
heart decompensation OR myocardial failure). The search was
performed using the following PICO format: (P) HF patients
treated with ivabradine, (I-C) HFrEF and HFpEF, (O) cardiovascu-
lar outcomes (heart rate, LVEF). The reference lists and citations
of relevant publications were also checked manually for addi-
tional eligible studies. PROSPERO was checked for ongoing and
completedmeta-analyses and systematic reviews.
2.2. Selection and eligibility
This meta-analysis includes all available randomized or non-
randomized, controlled or uncontrolled clinical trials and obser-
vational cohort studies conducted to determine the effect of ivab-
radine in patients with HFrEF or HFpEF. The selection criteria
were followed to include all studies involving HFrEF or HFpEF
patients where ivabradine was used to reduce cardiovascular
symptoms. Enrolled studies should show data for either one or
more of the following outcomes: (i) mortality outcomes (hospital
readmission for worsening HF, all-cause mortality, cardiovascu-
lar mortality), (ii) heart rate reduction or (iii) LVEF improvement.
Based on the fact that there is no available study in the literature
which includes both types of HF in the same population, we
defined two populations (HFrEF and HFpEF) by dividing the publi-
cations. Since the new classification and terminology of HF has
been introduced in 2016 in the ESC Guidelines (Ponikowski et al.
2016), the studies involved in this meta-analysis could not distin-
guish HFpEF from HFmrEF. Based on this and on the similarity of
the symptoms and diagnostic criteria, we included HFmrEF and
HFpEF patients in the same group (for the sake of simplicity we
refer this group as HFpEF from here on). As the purpose of this
meta-analysis is to compare the effect of ivabradine in HFrEF ver-
sus HFpEF patients, this study omits the comparison with pla-
cebo (with exception for mortality outcomes), which has been
described previously in patients with HFrEF (Hartmann et al.
2018). Studies eligible for inclusion required cardiovascular out-
comes measured after ivabradine treatment. Only studies on
adults were included. The articles focusing on children or ado-
lescents were excluded. Animal experiments and non-clinical
studies were also excluded. Further exclusion criteria were case
reports, comments, letters, abstracts, conference abstracts, or
ivabradine use in other populations of focus (e.g., stable angina
or atrial fibrillation).
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After the search, all the studies were imported into a reference
manager software (EndNote X7, Clarivate Analytics, PA, USA) to
remove duplicates by searching for studies with overlapping
publication date, author, and (or) title.
After the software controlled duplicate removal, authors checked
the remaining publications to remove all the duplicates, which
were not detected by the software. Studies were screened against
pre-identified eligibility criteria first by title, abstract, and then full
text. Each step was done by two authors (N.T. and A.P.) independ-
ently, and in the case of disagreement the discrepancy was solved
by a third reviewer (N.N.).
2.3. Data extraction
Data extraction from the selected articles was also done by two
authors independently (N.T. and A.P.). Numerical and texted data
were manually entered onto a standardized Excel 2010 sheet
(Microsoft Office 365, Microsoft, WA, USA) designed a priori. Data
were collected as follows: first author, publication year, study
design, countries, number of centers, recruitment period, geo-
graphical location, number of patients and basic demographics
(age, sex ratio), all the abovementioned mortality, cardiovascular
outcome parameters before ivabradine treatment, and the duration
of intervention.
2.4. Quality assessment
The risk of bias was assessed using the Cochrane risk of bias
tool (Higgins 2019) for RCTs, and the Newcastle–Ottawa Scale
(Wells 2013) has been edited to our study design and was used to
assess the quality of observational cohort studies. Each RCT was
assessed for random sequence generation (selection bias), alloca-
tion concealment (selection bias), blinding of participants and
personnel (performance bias), blinding of outcome assessors
(detection bias), incomplete outcome data (attrition bias), selective
outcome reporting (reporting bias), and other sources of bias— all
with ratings of low, high, or uncertain risk of bias. Cohort studies
were judged by the following items: representativeness of the inter-
vention group, selection of the control group, demonstration that
the outcomes of interest were not present at start of the study, com-
parability of cohorts on the basis of the design or analysis con-
trolled for confounders, assessment of outcome, adequacy of the
length of follow-up, and adequacy of quality of follow-up. Each
item was rated as ‘high risk’ (equals to 0), ‘low risk’ (equals to 1), or
‘unclear risk’ (equals to 0) corresponding to the definitions.
2.5. Statistical analysis
Statistical analysis was performed by experienced biostatisti-
cians (A.S. and A.V.) using Comprehensive Meta-analysis software
version 3 (Biostat, Englewood) for all analyses. For continuous
outcomes, differences inmeans with 95% confidence intervals (CIs)
and with standard error were calculated. For dichotomous outcomes,
event rates with 95% CI were calculated. Statistical significance was
defined as p < 0.05. Pooled estimates were calculated with random
effects model by using the DerSimonian–Laird method. Statistics
provided in this meta-analysis refer to the comparison between
Fig. 1. PRISMA flow diagram for study selection and inclusion. The initial search identified 1897 articles. After removing the overlapping
publications by electronic software and manual methods, 1532 studies were screened first by title and abstract, then by full text. A total
of 24 eligible studies met the inclusion criteria of this meta-analysis. [Colour online.]
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Table 1. Baseline characteristics of the included studies and populations in HFrEF group.








rate (bpm) Duration – follow up
Swedberg et al. (2010) RCT Multiple 677 October 2006–June 2009 3241 76 60.7 (11.2) 29 (5.1) 79.7 (9.5) 1 month, 1 year
Fox et al. (2008) RCT Multiple 781 December 2004–December 2006 2699 82 64.8 (8.6) 32 (5.6) 79.1 (8.5) 1, 3, 6 months, 1, 2 year
Darabantiu et al. (2016) Cohort study Romania 1 – 50 80 60 (12) 26 (7) 89 (10) 3, 6 months
Tsutsui et al. (2016) RCT Japan 73 December 2013–February 2015 62 84 (7.5) 6 weeks
Villacorta et al. (2019) RCT Brasil 1 – 10 90 56.2 (13.7) 33 (8.1) 89.1 (13.5) 6 months
Volterrani et al. (2011) RCT Italy 1 4 months 41 68 67.2 (9.5) 26.4 (4.7) 79.6 (11.2) 3 months
Hidalgo andAnguita (2017) RCT Spain 1 November 2013–April 2015 33 72 66.2 (15.4) 32.9 (8.7) 87.3 (10.6) 1 month
Sarullo et al. (2010) RCT Italy 1 – 30 75 52.7 (5.3) 30.6 (6) 75.7 (5) 3 months
Abdel-Salam et al. (2015) RCT Egypt 1 July 2011–March 2012 20 50 49.1 (15.7) 34 (4) 85 (12) 3 months
Sargento et al. (2013) Cohort study Portugal 1 October 2010–December 2010 25 68 63.8 (6.9) 30 (8) 79.2 (7.1) 3 months
Mansour et al. (2011) RCT Egypt 1 – 30 60 47 (13) 32.1 (6.1) 96 (15) 3 months, 1 year
Bagriy et al. (2015) Cohort study Ukraine 1 April 2011 33 64 63.2 (12.3) 37.4 (6.3) 82.7 (11.3) 5 months
Sisakian et al. (2016) RCT Armenia 1 – 27 81 58.3 (12.2) 30.6 (6.7) 81.3 (not shown) 3 months
Rayan et al. (2011) Cohort study Egypt 1 2009 35 60 44.2 (7.5) 32.6 (6.7) 101.5 (14.8) 3 months
Ordu et al. (2015) Cohort study Turkey 1 October 2013–August 2014 49 33 65.2 (8.7) 26.4 (5.3) 84.1 (8.8) 6 months
Jirak et al. (2018) Cohort study Germany 1 – 50 80 not shown 32.8 (1.7) 79.7 (1.1) 3, 6 months
Note: For every study, the intervention was ivabradine (7.5 mg) given twice daily. HFrEF, heart failure with reduced ejection fraction; RCT, randomized clinical trial; LVEF, left ventricular ejection fraction.
Table 2. Baseline characteristics of the included studies and populations in HFpEF group.









Komajda et al. (2017) RCT Multiple 86 June 2013–July 2015 95 38 72 (66–78)* 60 (54–66)* 75 (72–78)* Ivabradine 7.5 mg BID 8months
Cocco and Jerie (2013) RCT Switzerland 1 – 20 50 58.9 (2.3) 66 (5) 81 (3) Ivabradine 7.5 mg BID 3months
Kosmala et al. (2013) RCT Multiple 2 December 2011–December 2012 30 23 66.5 (8.5) 67 (7) 72 (7) Ivabradine 5 mg BID 7 days
Cacciapuoti et al. (2017) Cohort study Italy 1 October 2014–February 2016 25 64 67 (4) 48 (0.2) 81 (2) Ivabradine 5 mg BID 3months
Pal et al. (2015) RCT UnitedKingdom 2 December 2011–January 2014 22 35 74.6 (5.9) 64.5 (7.9) 75 (12) Ivabradine 7.5 mg BID 2, 4 weeks
Fox et al. (2014) RCT Multiple 1139 October 2009–April 2012 9550 73 65 (7.2) 56.4 (8.5) 77.1 (6.9) Ivabradine 7.5 mg BID 1, 2, 3, 6 months
Simantirakis et al. (2015) Cohort study Greece 1 – 48 35 55 (10) 60 (4) 85 (5) Ivabradine 7.5 mg BID 1, 6, 12 months
Riccioni et al. (2013) Cohort study Italy 2012 110 49 63 (5) 44 (5) 72 (4) Ivabradine 5 mg BID 1 month

































































































Fig. 2. The effect of ivabradine on hospital admission for (A) worsening heart failure, (B) all-cause mortality, and (C) cardiovascular
mortality in HFpEF compared to HFrEF. Forest plots represent the odds ratios (95% CI) of the outcomes. CI, confidence interval; HFpEF,
heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; EF, ejection fraction. [Colour online.]
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HFpEF and HfrEF. In the case of heart rate reduction and LVEF
improvement, we also performed the comparisons separately
including only RCT or just non-RCT studies. In the heart rate analy-
sis, sensitivity analysis and meta-regression was also conducted to
examine the potential confounding effect of the following fac-
tors: baseline heart rate values, age, and sex (%male). Results of
the meta-analysis are displayed graphically using forest plots. Het-
erogeneity was tested by using the Cochrane’s Q and the I2 statistics,
where I2 = 100% (Q – df)/Q, and represents themagnitude of the het-
erogeneity (moderate: 30%–60%, substantial: 50%–90%, considerable:
75%–100%) (Higgins 2019). A p value <0.1 was considered to indicate
significant heterogeneity. Publication bias and small study effect
was illustrated on funnel-plots and tested by Egger’s test, p < 0.1
indicating sign of bias.
3. Results
3.1. Study selection and characteristics
The electronic search conducted in the databases resulted in 1897
potential abstracts. After removing the duplicates, 1532 publica-
tions were selected first by title and abstracts, then 414 articles
were screened by full text. The reference lists and citations of rele-
vant publications were also checked manually for additional eligi-
ble studies, but we could not find any further suitable publications.
The flowchart of search and selection process is shown in Fig. 1.
Based on the inclusion criteria and full text selection, a total
number of 24 studies were included in the meta-analysis (Fox et al.
2008, 2014; Sarullo et al. 2010; Swedberg et al. 2010; Mansour 2011;
Rayan et al. 2011; Volterrani et al. 2011; Cocco and Jerie 2013;
Kosmala et al. 2013; Riccioni et al. 2013; Sargento et al. 2013; Abdel-
Salam et al. 2015; Bagriy et al. 2015; Ordu et al. 2015; Pal et al. 2015;
Simantirakis et al. 2015; Darabantiu 2016; Sisakian et al. 2016;
Tsutsui et al. 2016; Cacciapuoti et al. 2017; Hidalgo and Anguita
2017; Komajda et al. 2017; Jirak et al. 2018; Villacorta et al. 2019).
Among these articles there were only two studies in the HFrEF
group (Fox et al. 2008; Swedberg et al. 2010), and one in the HFpEF
group (Fox et al. 2014) that reported outcomes of hospital admission
for worseningHF, all-causemortality, and cardiovascularmortality.
Statistics were provided for these data, but because of the lownum-
ber of articles including mortality outcomes thorough conclusions
could not be accomplished. Other articles did not include these
data, but reported the most important cardiovascular outcomes of
interest, such as resting heart rate before and after the intervention
with ivabradine as well as LVEF. The selected articles have different
durations of ivabradine effect and follow-up of focus; however, the
majority of the included studies and this analysis focus on the
short-term effect of ivabradine treatment. Cardiovascular death or
hospital admission for worseningHF, all-causemortality, and cardi-
ovascular mortality are investigated after a 1 year follow-up. The
main baseline characteristics of the studies and the population
included in themeta-analysis are summarized in Table 1 and Table 2,
inHFrEF andHFpEF respectively.
Fig. 3. The effect of ivabradine on heart rate in HFpEF compared to HFrEF in pooled randomized and non-randomized clinical trials.
Heart rate analysis of pooled data showed significant difference among HFrEF vs. HFpEF. Data are presented in difference in means with
95% CI. CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
[Colour online.]
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Mortality endpoints of this study were all-cause mortality, car-
diovascular mortality, and hospital admission for worsening HF,
which were reported only in three of the selected articles (Fox
et al. 2008, 2014; Swedberg et al. 2010). We found two studies in
the HFrEF population and one in the HFpEF population, thus the
low amount of studies prevented us from providing detailed, and
presumably inappropriate, conclusions. To achieve reliable data,
the effect of ivabradine treatment on mortality outcomes was
compared with placebo in both HF types. Odds ratio (OR) ([95% CI],
I2 test p value) of cardiovascular death or hospital admission for
worsening HF in HFrEF was 0.85 ([0.752 to 0.962]; I2: 48%, p = 0.01),
which means ivabradine significantly reduces the risk of rehospi-
talization in HFrEF (Fig. 2A). In contrast, OR in HFpEF was 1.076
Fig. 4. Subgroup analysis of randomized clinical trials and non-randomized clinical trials on the effect of ivabradine on heart rate in
HFpEF compared to HFrEF. Significant difference in heart rate reduction disappeared when subgroup analysis was performed by the
design of the selected studies, however, it also showed a marked tendency that ivabradine could have stronger bradycardic effect in
HFrEF. Data are presented in difference in means with 95% CI. CI, confidence interval; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction. [Colour online.]
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Fig. 5. Sensitivity analysis of randomized clinical trials and non- randomized clinical trials on the effect of ivabradine on heart rate.
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. [Colour online.]
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([0.911 to 01.271]; I2: 0%, p = 0.39) resulting in no beneficial effect
of ivabradine in HFpEF and highlighting a significant difference
between HFrEF and HFpEF (p = 0.026) (Fig. 2A). A randomized con-
trolled trial of beta-blockers treatment in HFpEF patients showed
no improvement in cardiovascularmortality or HF hospitalizations
(Yamamoto 2015). The underlying mechanism of the beta-blocker-
induced failure to improve cardiovascular mortality and exercise
tolerance in HFpEF was probably the resultant negative inotropy.
This hypothesis suggests that pure heart rate reduction with
ivabradine could be able to improve outcomes as it has no nega-
tive inotropic effect. In contrast, OR of all-cause mortality and
cardiovascularmortality were 1.062 ([0.908 to 1.243]; I2: 0%, p = 0.451)
and 1.062 ([0.927 to 1.218]; I2: 0%, p = 0.386) in HFpEF, supporting
that heart rate reduction with ivabradine was also not associated
with a reduction in all-causemortality and cardiovascularmortality
(Figs. 2B and 2C). It seems that heart rate reduction alone may be
not enough to improve outcomes in HFpEF. Surprisingly, the OR
risk of all-cause mortality 0.951 ([0.943 to 1.073]; I2: 25%, p = 0.415)
and cardiovascular mortality 0.95 ([0.849 to 1.064]; I2: 5%, p = 0.377)
was also unchanged in HFrEF (Fig. 2B and 2C); however, individual
RCTs demonstrated a favourable decrease in cardiovascularmortal-
ity (Swedberg et al. 2010).
3.3. Cardiovascular endpoints
Altogether, we found data for heart rate before and after short-
term ivabradine treatment in 16 publications (Fox et al. 2008;
Sarullo et al. 2010; Mansour 2011; Rayan et al. 2011; Volterrani
et al. 2011; Cocco and Jerie 2013; Kosmala et al. 2013; Riccioni et al.
Fig. 6. Meta-regression of baseline heart rate, age, and sex (%male) on heart rate reduction with ivabradine. HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; CI, confidence interval; RCT, randomized clinical trial.
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2013; Sargento et al. 2013; Abdel-Salam et al. 2015; Bagriy et al.
2015; Pal et al. 2015; Simantirakis et al. 2015; Tsutsui et al. 2016;
Cacciapuoti et al. 2017; Hidalgo and Anguita 2017). Heart rate
analysis (difference in means [95% CI]; I2 test, p value) showed a
large decrease in both HFrEF (–17.646 beats/min [–21.724 to –13.569];
I2: 69%, p = 0.001) and HFpEF group (–11.434 beats/min [–15.874 to
–6.993]; I2: 90%, p < 0.001) (Fig. 3). Our results show that together,
for all the studies that report heart rate before and after ivabradine
treatment, the magnitude of heart rate reduction following ivabra-
dine adjustment is significantly larger inHFrEF compared toHFpEF
(p = 0.043, Fig. 3). As the design of the included studies are different,
subgroup analyses were performed to compare the effect of ivab-
radine separately in RCTs and non-RCT studies. Interestingly, sub-
group analysis showed no difference in heart rate reduction between
HFpEF and HFrEF (Fig. 4A and 4B). Ivabradine effectively decreased
baseline heart rates in non-RCTs in both HFrEF (–14.841 beats/min
[–20.29 to –9.391]; I2: 64%, p < 0.001) and HFpEF (–10.15 beats/min
[–15.777 to –4.524]; I2: 32%, p < 0.001) (Figs. 4A and 4B), although the
difference was not statistically significant (p = 0.241). In RCTs also,
heart rate reduction analysis showed a decrease in both HFrEF
(–18.770 beats/min [–23.889 to –13.651]; I2: 75%, p < 0.001) and HFpEF
(–12.041 beats/min [–18.02 to –6.062; I2: 93%, p < 0.001) (Figs. 4A and
4B). The magnitude of heart rate reduction showed a tendency to
differ between HFrEF and HFpEF in the RCTs, however it did not
reach the statistical significance (p = 0.094). Statistical analysis
revealed high heterogeneity between the studies. To identify the
reason and possible studies which can be responsible for the
high heterogeneity, meta-regressions on baseline parameters
were done to examine the possible impact of other variables on
the effect size. Meta-regression showed that baseline heart rate
could be an underlying reason of the high heterogeneity, as the
intervention effect increases as the baseline heart rate is higher
showing a significant linear correlation (Fig. 5A). Other potential
explanatory variables (i.e.: age, sex) did not affect the magnitude
of heart rate reduction by ivabradine treatment (Figs. 5B and 5C).
Sensitivity analysis did not find any study that was out of line and
that could influence the results of the statistics (Figs. 6A and 6B).
LVEF analysis revealed a significant improvement in HFrEF (5.936,
[4.199 to 7.672], I2: 23%, p< 0.001), also when comparedwith placebo
(p < 0.001, Fig. 7). Ivabradine caused no significant change on LVEF
in HFpEF (1.247, [–0.845 to 3.343], I2: 27%, p = 0.242). Regarding this
negligible effect in HFpEF and the fact that improvement of LVEF in
HFpEF could be detrimental, statistical comparison in respect of
LVEF betweenHFrEF andHFpEF is unnecessary.
3.4. Risk of bias within studies and publication bias
Risk of bias was assessed in 9 non-RCT studies (Rayan et al.
2011; Riccioni et al. 2013; Sargento et al. 2013; Bagriy et al. 2015;
Ordu et al. 2015; Simantirakis et al. 2015; Darabantiu et al. 2016;
Cacciapuoti et al. 2017; Jirak et al. 2018) and 15 RCTs (Swedberg
et al. 2010; Fox et al. 2008; Mansour 2011; Cocco and Jerie 2013;
Kosmala et al. 2013; Pal et al. 2015; Sisakian et al. 2016; Komajda
et al. 2017; Tsutsui et al. 2016; Villacorta et al. 2019; Volterrani
et al. 2011; Hidalgo and Anguita 2017; Sarullo et al. 2010; Abdel-
Salam et al. 2015; Fox et al. 2014). Results of the Cochrane Risk of
Bias Assessment Tool for RCTs and the results of the Newcastle–
Ottawa quality assessment scale for cohort studies are shown in
Fig. 8 and Fig. 9 in both populations. Because of the low number
of publications for LVEF outcomes, funnel plots were constructed
only for heart rate outcome in HFrEF and HFpEF population. In
studies involving HFrEF patients, the funnel plot showed symme-
try on visual inspection with p = 0.79 in Egger’s test, and studies
on HFpEF population showed a little asymmetry with p = 0.082;
however, publication bias was not large and was unlikely to alter
conclusions in both group (Fig. 10).
4. Discussion
RCTs (e.g., SHIFT-, BEAUTIFUL-, and EDIFY-trials; Fox et al. 2008;
Swedberg et al. 2010; Komajda et al. 2017) found significant effect of
ivabradine on heart rate both in HFpEF and HFrEF compared with
control, however ivabradine failed to improve cardiovascular out-
comes in HFpEF for unknown reasons (Fox et al. 2008; Komajda
et al. 2017). In this meta-analysis, we compared the effect of ivabra-
dine in the treatment of HF between HFpEF and HFrEF patients.
When RCTs and non-RCTs were pooled, we found significantly
improved bradycardic effect of ivabradine inHFrEF patients (Fig. 3).
In contrast, when RCTs and non-RCTs were analyzed separately,
statistically identical heart rate lowering effect of ivabradine was
Fig. 7. The effect of ivabradine on left ventricular ejection fraction in HFrEF. Data are presented in difference in means with 95% CI.
CI, confidence interval; HFrEF, heart failure with reduced ejection fraction. [Colour online.]
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found between HFpEF and HFrEF (Fig. 4); however, a clear tendency
of increased bradycardic effect of ivabradine in HFrEF still exists. It
was also found that ivabradine significantly improved the LVEF in
HFrEF patients (Fig. 7).
4.1. Pharmacological properties of ivabradine
Experimental studies on ivabradine have demonstrated that at
a concentration of 3 lM it reduces the pacemaker frequency in
isolated rabbit SA node by decreasing the slope of the diastolic
depolarization without any effect on action potential (AP) dura-
tion or on AP amplitude (Thollon et al. 1994). The the half maxi-
mal inhibitory concentration (IC50) for the If blockade is 2.8 lM
(Bois et al. 1996); however, Koncz et al. (2011) demonstrated that
ivabradine exerts a considerable inhibiting effect on IKr (delayed
rectifier potassium current), having IC50 of 3.5 lM. At this concentra-
tion, ivabradine provides approximately 60%–65% of If inhibition.
Furthermore, a marked IKr current inhibition will contaminate the
If inhibiting effect. The study by Koncz et al. (2011) also demonstrated
that in normal undiseased dog and in healthy human ventricular
myocardium, even 10 lM ivabradine has only marginal AP lengthen-
ing effect. In contrast,when the repolarization reservewas attenuated
(by 30 lMBaCl2), even 1 lM ivabradine causedmarked AP lengthen-
ing, indicating the IKr channel inhibiting role of ivabradine which
is prominent in the presence of attenuated repolarization.
Fig. 8. Results of the Cochrane Risk of Bias Assessment Tool for randomized clinical trials in (A) HFrEF and (B) HFpEF population. Studies
were judged by the following items where letters refer to: (A) Random sequence generation, (B) allocation concealment, (C) selective
reporting, (D) blinding of participants and personnel, (E) blinding of outcome assessment, (F) Incomplete outcome data, and (G) other
sources of bias. Green: low risk of bias; yellow: uncertain risk of bias; red: high risk of bias. HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction. [Colour online.]
Fig. 9. Results of the edited Newcastle–Ottawa quality assessment scale for cohort studies in (A) HFrEF and (B) HFpEF population. Studies
were judged by the following items where numbers refer to: (1) representativeness of the intervention group; (2) selection of the control
group; (3) demonstration that the outcomes of interest were not present at start of the study; (4) comparability of cohorts on the basis of
the design or analysis controlled for confounders; (5) assessment of outcome; (6) adequacy of the length of follow-up; (7) adequacy of
quality of follow-up. Each item was rated as ‘high risk’ (equals to 0), ‘low risk’ (equals to 1), or ‘unclear risk’ (equals to 0) corresponding to
the definitions. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. [Colour online.]
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4.2. Structural and electrical remodeling in HFrEF vs. HFpEF
Structurally, HFpEF can be characterized by concentric LV hy-
pertrophy with high LV mass/volume ratio and interstitial fibro-
sis. In contrast, HFrEF is characterized by progressive ventricular
dilatation, eccentric LV remodeling, low LV mass/volume ratio,
and decreasing amount of cardiomyocytes replaced with fibrosis
(Konstantinou et al. 2013; Asrar Ul Haq et al. 2014; Borlaug 2014).
Electrical remodeling is a common feature of HF (Table 3), how-
ever, it manifests differently between HFrEF and HFpEF. Amodel-
ing study demonstrated longer AP duration in HFrEF via the
increased late Na+ current and the decreased outward K+ currents
(Glitsch 2001; Workman et al. 2003; Bueno-Orovio et al. 2014;
Adeniran et al. 2015). Ito (transient outward potassium current)
was also found to be decreased in HFrEF causing considerable AP
prolongation in human (Tomaselli et al. 1994; Tomaselli and
Marban 1999; Tomaselli and Zipes 2004). The hallmark of HFpEF
is the impaired diastolic relaxation, which can be attributable to
the decreased Na+/Ca2+ exchanger (NCX) current activity in the
presence of reduced sarcoplasmic reticulum (SR) Ca2+ content
and smaller release, compared with healthy control. In con-
trast, in HFrEF, the NCX activity is increased, causing significant
diastolic Ca2+ leak and markedly decreased SR Ca2+ content
(Table 3). Taken altogether, the released Ca2+ is lower in the case
of HFrEF compared with HFpEF, while the ICaL (L-type calcium
current) does not differ significantly between the two types of
HF. It is important to note that the decreased NCX current in
HFpEF contributes in AP duration shortening while the increased
exchanger function in HFrEF lengthens the AP duration. Previous
Fig. 10. Funnel plots for studies in heart rate in HFpEF and HFrEF groups. HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction.
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study demonstrated the important role of NCX in setting the actual
length of the AP (Hurtado et al. 2005). The important role of the
NCX in HF raises the possibility that selective NCX inhibition could
effectively control the actual duration of the AP. Cho et al. (2017)
in rat HFpEF model demonstrated Ito downregulation and conse-
quently AP prolongation and prolonged electrocardiogram (ECG)
QT interval. The late Na+ current, and the inward rectifier K+ cur-
rent were also remodeled (Borbély et al. 2005; Selby et al. 2011; Zile
and Gaasch 2011; Trenor et al. 2012; Gomez et al. 2014). Two studies
compared the continuous QT intervals between HFpEF and HFrEF.
Both papers demonstrated larger continuous QT in the case of
HFrEF (454 6 42 vs. 427 6 42 ms and 499 6 50 vs. 453 6 43 ms)
(Cenkerova et al. 2016; Hendry et al. 2016) indicatingmore attenu-
ated repolarization reserve in HFrEF patients compared with
HFpEF.
4.3. Identical effects of ivabradine on heart rate in HFrEF
versus HFpEF
Separation of RCTs and non-RCTs resulted in identical brady-
cardic effect of ivabradine in HFpEF and HFrEF; however, despite
the lack of statistical significance in heart rate reduction, there is
a mild difference between the two groups, which needs further
investigation. When the available data were pooled (i.e., RCT and
non-RCT) statistical analysis revealed significantly enchanced
bradycardic effect of ivabradine in HFrEF, therefore, it is plausi-
ble that ivabradine could have stronger bradycardic effect in
HFrEF, which could be the result of two synergistic mechanisms
established by the electrical remodeling. (i) It was found that the
expression level of HCN channels is decreased in HFrEF providing
reduced pacemaker If during diastolic depolarization of the sinus
node cells. In this case the effect of ivabradine is larger because
of the increased susceptibility (i.e., decreased current density)
of the diastolic depolarization (Rocchetti et al. 2000; Zaza and
Lombardi 2001; Kohajda et al. 2019). (ii) The IKr inhibitory effect of
ivabradine is not negligible as the dose causing 60%–70% inhibi-
tion of If also exerts an inhibition of 50% on the IKr (Koncz et al.
2011). As IKr inhibition also lengthens the sinus node cycle length
it could also contribute in the frequency decrease (Boyett et al.
2000). The initial hypothesis, suggesting that the efficacy of ivab-
radine treatment would be progression dependent, was not con-
firmed. Nevertheless, the large heterogeneities between studies
may considerably limit more precise statistical analysis.
4.4. Improved ejection fraction in HFrEF after ivabradine
treatment
Structural or functional impairment of LV filling and ejection
of blood in HF patients results in symptomatic LV dysfunction
causing impaired LVEF in HFrEF. The aim in the treatment of HF
is to improve symptoms, slow the progression of the cardiac fail-
ure, and to decrease the HF associated mortality in patients.
Heart rate reduction accompanied by LVEF improvement should
be beneficial in HFrEF patients. All four RCT studies reported
that ejection fraction is improved in HFrEF patients after ivabra-
dine treatment. As reduced LVEF is a hallmark characteristic of
HFrEF, this secondary effect of ivabradine could be beneficial and
may contribute to the improved symptoms and the decreased
mortality observed in HFrEF. As previously mentioned, HFrEF
patients have significantly longer ECG QT interval due to the
downregulation of IKr, Ito, and IKs currents, causing impaired
repolarization reserve (Beuckelmann et al. 1993; Tsuji et al. 2000;
Cenkerova et al. 2016; Hendry et al. 2016) (Table 3). It is feasible
that the additional IKr inhibition effect of ivabradine could cause
larger QT-lengthening via the attenuated repolarization reserve.
The prolonged QT interval and the prolonged plateau phase of
the ventricular AP provide increased Ca2+ influx, enhancing the
available Ca2+ for sarcoplasmic-endoplasmic reticulum calcium
ATPase. As the SR Ca2+ content is increased, the magnitude of the
released Ca2+ is also enhanced providing increased LV performance.
4.5. Differences in comorbidities in HFpEF and HFrEF
HFrEF and HFpEF exerts some important differences in comor-
bidities. HFrEF patients are predominantly males having increased
susceptibility tomyocardial infarction and cardiomyocytes loss (Ho
et al. 2013). In contrast, HFpEF patients are more likely to be older
with a 2-fold predominance of females (Lee et al. 2009). It is impor-
tant to note that HFpEF patients have higher incidence of different
comorbidities such as pulmonary disease, stroke, hypertension,
type-2 diabetes mellitus, anaemia, stroke, gout, and cancer of any
type (Ergatoudes et al. 2019). The mortality risk of comorbidities,
however, are similar between HFpEF and HFrEF (Felker et al. 2006;
Ather et al. 2012; Smith et al. 2013), the incidence of hospitalization
caused by comorbidities are higher in HFpEF (Streng et al. 2018).
This important differencemay indicate that ivabradine has limited
efficacy in HFpEF because of the higher rate of comorbidities-
related illness.
Table 3. Summary of results of ion channel expression changes in HFrEF in sinus node and in ventricular muscle.
Ion channel
Sinus node (or atrial myocytes*) Ventricle
Results Model Reference Results Model Reference
ICaL Decreased* Human (Ouadid et al. 1995) Decreased Human (Ouadid et al. 1995)
Decreased* Dog (Li et al. 2000) Not altered Human (Beuckelmann et al. 1992)
Not altered Rabbit (Verkerk et al. 2003) Not altered Human (Mewes and Ravens 1994)
ICaT Not altered* Dog (Li et al. 2000) Not altered Human (Beuckelmann et al. 1991, 1992)
Not altered Rabbit (Verkerk et al. 2003)
If Decreased Rabbit (Verkerk et al. 2003) Increased Rabbit (Nattel et al. 2007)
Decreased Dog (Zicha et al. 2005) Not altered Human (Hoppe et al. 1998)
Increased* Dog (Zicha et al. 2005)
IKr Not altered Rabbit (Verkerk et al. 2003) Not altered Dog (Li et al. 2002)
Not altered* Dog (Li et al. 2000) Decreased Rabbit (Tsuji et al. 2000)
Ito Not altered Rabbit (Verkerk et al. 2003) Decreased Human (Beuckelmann et al. 1993)
Decreased* Dog (Li et al. 2000)
INCX Not altered Rabbit (Verkerk et al. 2003) Increased Human (Flesch et al. 1996)
Increased* Dog (Li et al. 2000) Increased Human (Studer et al. 1994)
Note: Ion channel expression likely differ in HFpEF vs. HFrEF, however, there is still hardly any experimental data on ion channel expression and ionic current
changes in HFpEF, thus this table demonstrates only the electrophysiological changes in HFrEF. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction; ICaL, L-type calcium current; ICaT, T-type calcium current; If, pacemaker (“funny”) current; IKr, delayed rectifier potassium
current; Ito, transient outward potassium current; INCX, sodium-calcium exchanger current.
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Our study has the following limitations: (i) The comparison
was performed on two populations, as we could not find any
paper comparing HFpEF and HFrEF in one study. This lack of
information indicates the necessity of parallel elucidation of
ivabradine effect on HFpEF and HFrEF patients in clinical trials.
(ii) Since the new classification of HF by the ESC was introduced
in 2016 (Ponikowski et al. 2016), the studies involved in this meta-
analysis could not distinguish HFpEF fromHFmrEF. Based on this
and the similarity of the symptoms, two articles that included
HFpEF populations which now are considered HFmrEF were
merged into those with HFpEF. (iii) Based on the low number of
clinical studies in HF treated with ivabradine, this meta-analysis
includes different study types: randomized or non-randomized,
controlled or uncontrolled clinical trials and observational cohort
studies, and there was significant heterogeneity in some of the out-
comes that were analyzed in thismeta-analysis.
6. Conclusions
In this study we found that ivabradine significantly increases
the LV performance in HFrEF and exerts a possible tendency to
have stronger bradycardic effect in HFrEF compared with HFpEF.
These effects, coupled with the previously reported higher preva-
lence of non-cardiac comorbidities in HFpEF, may contribute to
the observed disparate results of ivabradine between HFpEF and
HFrEF.
Conflict of interest
The authors declare that the research was conducted in the ab-
sence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Authors contribution
Norbert Nagy, Attila Farkas, Péter Hegyi and András Varró con-
tributed conception and design of the study. Noémi Tóth and
Alexandra Polyák performed the literature search and data
extraction from the enrolled studies and assessed the risks of
bias in the studies involved. Alexandra Soós and Alex Váradi per-
formed the statistical analysis and created the forest plot and
funnel plot figures. Margit Solymár made substantial help regis-
tering the study in PROSPERO database. Benedek Tinusz, Anna
Vágvölgyi, Andrea Orosz made substantial contributions to the
analysis. Noémi Tóth, Norbert Nagy, and Attila Farkas drafted the
manuscript. All the authors edited, read, and approved the final
version of themanuscript.
Funding sources
This work was supported by grants from the National Research
Development and Innovation Office (FK-129117 (for NN), GINOP-2.3.2-
15-2016-00006 and GINOP 2.3.2-15-2016-00048, the LIVE LONGER
EFOP-3.6.2-16-2017-00006 project, the János Bolyai Research Scholar-
ship of the Hungarian Academy of Sciences (for NN), the ÚNKP-
20-5-SZTE-165 and ÚNKP-20-3-SZTE-126 New National Excellence
Program of the Ministry for Innovation and Technology (for
Norbert Nagy and Noémi Tóth).
References
Abdel-Salam, Z., Rayan, M., Saleh, A., Abdel-Barr, M.G., Hussain, M., and
Nammas, W. 2015. I(f) current inhibitor ivabradine in patients with
idiopathic dilated cardiomyopathy: impact on the exercise tolerance
and quality of life. Cardiol. J. 22(2): 227–232. doi:10.5603/CJ.a2014.0057. PMID:
25179314.
Adeniran, I., MacIver, D.H., Hancox, J.C., and Zhang, H. 2015. Abnormal cal-
cium homeostasis in heart failure with preserved ejection fraction is
related to both reduced contractile function and incomplete relaxation:
an electromechanically detailed biophysical modeling study. Front. Phys-
iol. 6: 78. doi:10.3389/fphys.2015.00078. PMID:25852567.
Asrar Ul Haq, M., Mutha, V., Rudd, N., Hare, D.L., and Wong, C. 2014. Heart
failure with preserved ejection fraction - unwinding the diagnosis mys-
tique. Am. J. Cardiovasc. Dis. 4(3): 100–113. PMID:25360388.
Ather, S., Chan, W., Bozkurt, B., Aguilar, D., Ramasubbu, K., Zachariah, A.A.,
et al. 2012. Impact of noncardiac comorbidities on morbidity and mortality
in a predominantly male population with heart failure and preserved versus
reduced ejection fraction. J. Am. Coll. Cardiol. 59(11): 998–1005. doi:10.1016/j.
jacc.2011.11.040. PMID:22402071.
Bagriy, A.E., Schukina, E.V., Samoilova, O.V., Pricolota, O.A., Malovichko, S.I.,
Pricolota, A.V., et al. 2015. Addition of ivabradine to beta-blocker improves
exercise capacity in systolic heart failure patients in a prospective, open-label
study. Adv. Ther. 32(2): 108–119. doi:10.1007/s12325-015-0185-5. PMID:25700807.
Beuckelmann, D.J., Nabauer, M., and Erdmann, E. 1991. Characteristics of
calcium-current in isolated human ventricular myocytes from patients
with terminal heart failure. J. Mol. Cell. Cardiol. 23(8): 929–937. doi:10.1016/
0022-2828(91)90135-9. PMID:1658345.
Beuckelmann, D.J., Nabauer, M., and Erdmann, E. 1992. Intracellular calcium
handling in isolated ventricular myocytes from patients with terminal heart
failure. Circulation, 85(3): 1046–1055. doi:10.1161/01.CIR.85.3.1046. PMID:
1311223.
Beuckelmann, D.J., Nabauer, M., and Erdmann, E. 1993. Alterations of K+
currents in isolated human ventricular myocytes from patients with ter-
minal heart failure. Circ. Res. 73(2): 379–385. doi:10.1161/01.RES.73.2.379.
PMID:8330380.
Bohm, M., Swedberg, K., Komajda, M., Borer, J.S., Ford, I., Dubost-Brama, A.,
et al. 2010. Heart rate as a risk factor in chronic heart failure (SHIFT): the
association between heart rate and outcomes in a randomised placebo-
controlled trial. Lancet, 376(9744): 886–894. doi:10.1016/S0140-6736(10)
61259-7. PMID:20801495.
Bois, P., Bescond, J., Renaudon, B., and Lenfant, J. 1996. Mode of action of
bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.
Br. J. Pharmacol. 118(4): 1051–1057. doi:10.1111/j.1476-5381.1996.tb15505.x. PMID:
8799581.
Borbély, A., van der Velden, J., Papp, Z., Bronzwaer, J.G.F., Edes, I., Stienen, G.J.M.,
et al. 2005. Cardiomyocyte stiffness in diastolic heart failure. Circulation, 111(6):
774–781. doi:10.1161/01.CIR.0000155257.33485.6D. PMID:15699264.
Borer, J.S., Fox, K., Jaillon, P., and Lerebours, G. Ivabradine Investigators Group.
2003. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in
stable angina: a randomized, double-blind, multicentered, placebo-controlled
trial. Circulation, 107(6): 817–823. doi:10.1161/01.CIR.0000048143.25023.87.
PMID:12591750.
Borlaug, B.A. 2014. The pathophysiology of heart failure with preserved ejection
fraction. Nat. Rev. Cardiol. 11(9): 507–515. doi:10.1038/nrcardio.2014.83.
PMID:24958077.
Boyett, M.R., Honjo, H., and Kodama, I. 2000. The sinoatrial node, a hetero-
geneous pacemaker structure. Cardiovasc. Res. 47(4): 658–687. doi:10.1016/
S0008-6363(00)00135-8. PMID:10974216.
Bueno-Orovio, A., Sanchez, C., Pueyo, E., and Rodriguez, B. 2014. Na/K pump
regulation of cardiac repolarization: insights from a systems biology
approach. Pflugers Arch. Eur. J. Physiol. 466(2): 183–193. doi:10.1007/
s00424-013-1293-1. PMID:23674099.
Busseuil, D., Shi, Y., Mecteau, M., Brand, G., Gillis, M.A., Thorin, E., et al.
2010. Heart rate reduction by ivabradine reduces diastolic dysfunction
and cardiac fibrosis. Cardiology, 117(3): 234–242. doi:10.1159/000322905.
PMID:21212673.
Cacciapuoti, F., Magro, V.M., Caturano, M., Lama, D., and Cacciapuoti, F.
2017. The role of ivabradine in diastolic heart failure with preserved ejec-
tion fraction. A Doppler-echocardiographic study. J. Cardiovasc. Echogr.
27(4): 126–131. doi:10.4103/jcecho.jcecho_6_17. PMID:29142810.
Cenkerova, K., Dubrava, J., Pokorna, V., Kaluzay, J., and Jurkovicova, O.
2016. Prognostic value of echocardiography and ECG in heart failure with
preserved ejection fraction. Bratisl. Lek. Listy. 117(7): 407–412. doi:10.4149/
BLL_2016_080. PMID:27546546.
Cho, J.H., Zhang, R., Kilfoil, P.J., Gallet, R., de Couto, G., Bresee, C., et al.
2017. Delayed repolarization underlies ventricular arrhythmias in rats
with heart failure and preserved ejection fraction. Circulation, 136(21):
2037–2050. doi:10.1161/CIRCULATIONAHA.117.028202. PMID:28974519.
Cocco, G., and Jerie, P. 2013. Comparison between ivabradine and low-dose
digoxin in the therapy of diastolic heart failure with preserved left ven-
tricular systolic function. Clin. Pract. 3(2): e29. doi:10.4081/cp.2013.e29.
PMID:24765517.
Darabantiu, D., Lala, R., Moldovan, A.P., Pilat, L., Puschita, M., and Christodorescu, R.
2016. Ivabradine initiation during vulnerable phase in patients hospitalized
for decompensated heart failure. Rom. J. Cardiol. 26: 460–466.
DiFrancesco, D. 1993. Pacemaker mechanisms in cardiac tissue. Annu. Rev.
Physiol. 55: 455–472. doi:10.1146/annurev.ph.55.030193.002323. PMID:7682045.
Ergatoudes, C., Schaufelberger, M., Andersson, B., Pivodic, A., Dahlström, U., and
Fu, M. 2019. Non-cardiac comorbidities and mortality in patients with heart
failure with reduced vs. preserved ejection fraction: a study using the Swed-
ish Heart Failure Registry. Clin. Res. Cardiol. 108(9): 1025–1033. doi:10.1007/
s00392-019-01430-0. PMID:30788622.
Felker, G.M., Shaw, L.K., Stough, W.G., and O’Connor, C.M. 2006. Anemia in
patients with heart failure and preserved systolic function. Am. Heart J.
151(2): 457–462. doi:10.1016/j.ahj.2005.03.056. PMID:16442914.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
14 Can. J. Physiol. Pharmacol. Vol. 00, 0000
























































Flesch, M., Schwinger, R.H.G., Schiffer, F., Frank, K., S€udkamp, M., Kuhn-Regnier, F.,
et al. 1996. Evidence for functional relevance of an enhanced expression of
the Na(+)-Ca2+ exchanger in failing human myocardium. Circulation, 94(5):
992–1002. doi:10.1161/01.CIR.94.5.992. PMID:8790037.
Fox, K., Ford, I., Steg, P.G., Tendera, M., and Ferrari, R. BEAUTIFUL Investiga-
tors. 2008. Ivabradine for patients with stable coronary artery disease
and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, dou-
ble-blind, placebo-controlled trial. Lancet, 372(9641): 807–816. doi:10.1016/
S0140-6736(08)61170-8. PMID:18757088.
Fox, K., Ford, I., Steg, P.G., Tardif, J.-C., Tendera, M., and Ferrari, R. 2014.
Ivabradine in stable coronary artery disease. N. Engl. J. Med. 371(25):
1091–1099. doi:10.1056/NEJMc1413158. PMID:25517717.
Glitsch, H.G. 2001. Electrophysiology of the sodium-potassium-ATPase in cardiac
cells. Physiol. Rev. 81(4): 1791–1826. doi:10.1152/physrev.2001.81.4.1791. PMID:
11581502.
Gomez, J.F., Cardona, K., Romero, L., Ferrero, J.M., Jr., and Trenor, B. 2014.
Electrophysiological and structural remodeling in heart failure modulate
arrhythmogenesis. 1D simulation study. PLoS One, 9(9): e106602. doi:10.1371/
journal.pone.0106602. PMID:25191998.
Hartmann, C., Bosch, N.L., de Aragao Miguita, L., Tierie, E., Zytinski, L., and
Baena, C.P. 2018. The effect of ivabradine therapy on heart failure
patients with reduced ejection fraction: a systematic review and meta-
analysis. Int. J. Clin. Pharm. 40(6): 1443–1453. doi:10.1007/s11096-018-0715-8.
PMID:30173307.
Hendry, P.B., Krisdinarti, L., and Erika, M. 2016. Scoring system based on
electrocardiogram features to predict the type of heart failure in patients
with chronic heart failure. Cardiol. Res. 7(3): 110–116. doi:10.14740/cr473w.
PMID:28197277.
Hidalgo, F.J., and Anguita, M. 2017. Ivabradine in acute decompensated sys-
tolic heart failure. Int. J. Cardiol. 235: 198. doi:10.1016/j.ijcard.2017.02.060.
PMID:28342497.
Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and
Welch, V.A. 2019. Cochrane handbook for systematic reviews of interven-
tions. John Wiley & Sons, Chichester, UK.
Ho, J.E., Lyass, A., Lee, D.S., Vasan, R.S., Kannel, W.B., Larson, M.G., and
Levy, D. 2013. Predictors of new-onset heart failure: differences in pre-
served versus reduced ejection fraction. Circ. Heart Fail. 6(2): 279–286.
doi:10.1161/CIRCHEARTFAILURE.112.972828. PMID:23271790.
Hoppe, U.C., Jansen, E., S€uDkamp, M., and Beuckelmann, D.J. 1998. Hyperpo-
larization-activated inward current in ventricular myocytes from normal and
failing human hearts. Circulation, 97(1): 55–65. doi:10.1161/01.CIR.97.1.55.
PMID:9443432.
Hurtado, C., Ander, B.P., Maddaford, T.G., Lukas, A., Hryshko, L.V., and Pierce, G.N.
2005. Adenovirally delivered shRNA strongly inhibits Na+-Ca2+ exchanger
expression but does not prevent contraction of neonatal cardiomyocytes.
J. Mol. Cell. Cardiol. 38(4): 647–654. doi:10.1016/j.yjmcc.2005.02.007. PMID:
15808841.
Inamdar, A.A., and Inamdar, A.C. 2016. Heart failure: diagnosis, management
and utilization. J. Clin. Med. 5(7): 62. doi:10.3390/jcm5070062. PMID:27367736.
Jirak, P., Fejzic, D., Paar, V., Wernly, B., Pistulli, R., Rohm, I., et al. 2018.
Influences of Ivabradine treatment on serum levels of cardiac biomarkers
sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Acta Pharmacol. Sin. 39(7): 1189–1196. doi:10.1038/aps.2017.167. PMID:
29239349.
Kannel, W.B., Kannel, C., Paffenbarger, R.S., Jr., and Cupples, L.A. 1987. Heart
rate and cardiovascular mortality: the Framingham Study. Am Heart J. 113(6):
1489–1494. doi:10.1016/0002-8703(87)90666-1. PMID:3591616.
Kohajda, Z., Tóth, N., Szlovák, J., Loewe, A., Bitay, G., Gazdag, P., et al. 2019.
Novel Na+/Ca2+ exchanger inhibitor ORM-10962 supports coupled function
of funny-current and Na+/Ca2+ exchanger in pacemaking of rabbit sinus
node tissue. Front. Pharmacol. 10: 1632. doi:10.3389/fphar.2019.01632. PMID:
32063850.
Komajda, M., Isnard, R., Cohen-Solal, A., Metra, M., Pieske, B., Ponikowski, P.,
et al. 2017. Effect of ivabradine in patients with heart failure with preserved
ejection fraction: the EDIFY randomized placebo-controlled trial. Eur. J. Heart
Fail. 19(11): 1495–1503. doi:10.1002/ejhf.876. PMID:28462519.
Koncz, I., Szel, T., Bitay, M., Cerbai, E., Jaeger, K., Fulop, F., et al. 2011. Electro-
physiological effects of ivabradine in dog and human cardiac preparations:
potential antiarrhythmic actions. Eur. J. Pharmacol. 668(3): 419–426.
doi:10.1016/j.ejphar.2011.07.025. PMID:21821019.
Konstantinou, D.M., Chatzizisis, Y.S., and Giannoglou, G.D. 2013. Pathophys-
iology-based novel pharmacotherapy for heart failure with preserved
ejection fraction. Pharmacol. Ther. 140(2): 156–166. doi:10.1016/j.pharm-
thera.2013.05.012. PMID:23792088.
Kosmala, W., Holland, D.J., Rojek, A., Wright, L., Przewlocka-Kosmala, M.,
and Marwick, T.H. 2013. Effect of If-channel inhibition on hemodynamic
status and exercise tolerance in heart failure with preserved ejection fraction:
a randomized trial. J. Am. Coll. Cardiol. 62(15): 1330–1338. doi:10.1016/j.jacc.
2013.06.043. PMID:23916925.
Lee, D.S., Gona, P., Vasan, R.S., Larson, M.G., Benjamin, E.J., Wang, T.J., et al.
2009. Relation of disease pathogenesis and risk factors to heart failure
with preserved or reduced ejection fraction: insights from the framing-
ham heart study of the national heart, lung, and blood institute. Circulation,
119(24): 3070–3077. doi:10.1161/CIRCULATIONAHA.108.815944. PMID:19506115.
Li, D., Melnyk, P., Feng, J., Wang, Z., Petrecca, K., Shrier, A., et al. 2000.
Effects of experimental heart failure on atrial cellular and ionic electro-
physiology. Circulation, 101(22): 2631–2638. doi:10.1161/01.CIR.101.22.2631.
PMID:10840016.
Li, G.R., Lau, C.P., Ducharme, A., Tardif, J.C., and Nattel, S. 2002. Transmural
action potential and ionic current remodeling in ventricles of failing ca-
nine hearts. Am. J. Physiol. Heart Circ. Physiol. 283(3): H1031–H1041.
doi:10.1152/ajpheart.00105.2002. PMID:12181133.
Mansour, S., Youssef, A., Rayan, M., and Ayman Saleh, M. 2011. Efficacy of
ivabradine in idiopathic dilated cardiomyopathy patients with chronic
heart failure. Egypt. Heart J. 63: 79–85. doi:10.1016/j.ehj.2011.09.001.
Mewes, T., and Ravens, U. 1994. L-type calcium currents of human myocytes
from ventricle of non-failing and failing hearts and from atrium. J. Mol.
Cell. Cardiol. 26(10): 1307–1320. doi:10.1006/jmcc.1994.1149. PMID:7869391.
Nattel, S., Maguy, A., Le Bouter, S., and Yeh, Y.H. 2007. Arrhythmogenic ion-
channel remodeling in the heart: heart failure, myocardial infarction,
and atrial fibrillation. Physiol. Rev. 87(2): 425–456. doi:10.1152/physrev.
00014.2006. PMID:17429037.
Ordu, S., Yildiz, B.S., Alihanoglu, Y.I., Ozsoy, A., Tosun, M., Evrengul, H.,
et al. 2015. Effects of ivabradine therapy on heart failure biomarkers. Car-
diol. J. 22(5): 501–509. doi:10.5603/CJ.a2015.0012. PMID:25733317.
Ouadid, H., Albat, B., and Nargeot, J. 1995. Calcium currents in diseased
human cardiac cells. J. Cardiovasc. Pharmacol. 25(2): 282–291. doi:10.1097/
00005344-199502000-00014. PMID:7752654.
Pal, N., Sivaswamy, N., Mahmod, M., Yavari, A., Rudd, A., Singh, S., et al. 2015.
Effect of selective heart rate slowing in heart failure with preserved ejection
fraction. Circulation, 132(18): 1719–1725. doi:10.1161/CIRCULATIONAHA.115.
017119. PMID:26338956.
Palatini, P., and Julius, S. 2004. Elevated heart rate: a major risk factor for
cardiovascular disease. Clin. Exp. Hypertens. 26(7–8): 637–644. doi:10.1081/
CEH-200031959. PMID:15702618.
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J.,
et al. 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute
and chronic heart failure: The Task Force for the diagnosis and treat-
ment of acute and chronic heart failure of the European Society of Cardi-
ology (ESC). Developed with the special contribution of the Heart Failure
Association (HFA) of the ESC. Eur. J. Heart Fail. 18(8): 891–975. doi:10.1002/
ejhf.592. PMID:27207191.
Rayan, M., Tawfik, M., Alabd, A., and Gamal, A. 2011. Ivabradine, a novel
heart rate slower: Is it a sword of double blades in patients with idio-
pathic dilated cardiomyopathy? Anadolu Kardiyol. Derg. 11(5): 402–406.
doi:10.5152/akd.2011.110. PMID:21712169.
Reil, J.C., Hohl, M., Reil, G.H., Granzier, H.L., Kratz, M.T., Kazakov, A., et al.
2013. Heart rate reduction by If-inhibition improves vascular stiffness
and left ventricular systolic and diastolic function in a mouse model of
heart failure with preserved ejection fraction. Eur. Heart J. 34(36): 2839–
2849. doi:10.1093/eurheartj/ehs218. PMID:22833515.
Riccioni, G., Masciocco, L., Benvenuto, A., Saracino, P., De Viti, D.,
Massari, F., et al. 2013. Ivabradine improves quality of life in subjects
with chronic heart failure compared to treatment with beta-blockers: results
of a multicentric observational APULIA study. Pharmacology, 92(5–6): 276–
280. doi:10.1159/000355169. PMID:24296869.
Rocchetti, M., Malfatto, G., Lombardi, F., and Zaza, A. 2000. Role of the
input/output relation of sinoatrial myocytes in cholinergic modulation of
heart rate variability. J. Cardiovasc. Electrophysiol. 11(5): 522–530. doi:10.1111/
j.1540-8167.2000.tb00005.x. PMID:10826931.
Sargento, L., Satendra, M., Longo, S., Lousada, N., and Palma dos Reis, R.
2013. Early NT-proBNP decrease with ivabradine in ambulatory patients
with systolic heart failure. Clin. Cardiol. 36(11): 677–682. doi:10.1002/
clc.22183. PMID:23929789.
Sarullo, F.M., Fazio, G., Puccio, D., Fasullo, S., Paterna, S., Novo, S., et al.
2010. Impact of ‘‘off-label’’ use of ivabradine on exercise capacity, gas
exchange, functional class, quality of life, and neurohormonal modulation in
patients with ischemic chronic heart failure. J. Cardiovasc. Pharmacol. Ther.
15(4): 349–355. doi:10.1177/1074248410370326. PMID:20940450.
Selby, D.E., Palmer, B.M., LeWinter, M.M., and Meyer, M. 2011. Tachycardia-
induced diastolic dysfunction and resting tone in myocardium from
patients with a normal ejection fraction. J. Am. Coll. Cardiol. 58(2): 147–
154. doi:10.1016/j.jacc.2010.10.069. PMID:21718911.
Simantirakis, E.N., Nakou, E.S., Kallergis, E.M., Arkolaki, E.G., Patrianakos, A.P.,
Papakonstantinou, P.E., et al. 2015. Long-term effect of If-channel inhibition
on diastolic function and exercise capacity in heart failure patients with
preserved ejection fraction. Int. J. Cardiol. 187: 9–11. doi:10.1016/j.ijcard.
2015.03.313. PMID:25828300.
Sisakian, H., Sargsyan, T., and Khachatryan, A. 2016. Effect of selective heart
rate reduction through sinus node If current inhibition on severely
impaired left ventricular diastolic dysfunction in patients with chronic
heart failure. Acta Cardiol. 71(3): 317–322. doi:10.1080/AC.71.3.3152092.
PMID:27594127.
Smith, D.H., Thorp, M.L., Gurwitz, J.H., McManus, D.D., Goldberg, R.J.,
Allen, L.A., et al. 2013. Chronic kidney disease and outcomes in heart fail-
ure with preserved versus reduced ejection fraction: the Cardiovascular
Research Network PRESERVE Study. Circ. Cardiovasc. Qual. Outcomes, 6(3):
333–342. doi:10.1161/CIRCOUTCOMES.113.000221. PMID:23685625.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Tóth et al. 15
























































Streng, K.W., Nauta, J.F., Hillege, H.L., Anker, S.D., Cleland, J.G., Dickstein, K.,
et al. 2018. Non-cardiac comorbidities in heart failure with reduced, mid-
range and preserved ejection fraction. Int. J. Cardiol. 271: 132–139. doi:10.1016/
j.ijcard.2018.04.001. PMID:30482453.
Studer, R., Reinecke, H., Bilger, J., Eschenhagen, T., Bohm, M., Hasenfuss, G.,
et al. 1994. Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage
human heart failure. Circ. Res. 75(3): 443–453. doi:10.1161/01.RES.75.3.443.
PMID:8062418.
Swedberg, K., Komajda, M., Böhm, M., Borer, J.S., Ford, I., Dubost-Brama, A.,
et al. 2010. Ivabradine and outcomes in chronic heart failure (SHIFT): a
randomised placebo-controlled study. Lancet, 376(9744): 875–885. doi:10.1016/
S0140-6736(10)61198-1. PMID:20801500.
Tanboga, _I.H., Topçu, S., Aksakal, E., Gulcu, O., Aksakal, E., Aksu, U., et al.
2016. The risk of atrial fibrillation with ivabradine treatment: a meta-
analysis with trial sequential analysis of more than 40000 patients. Clin.
Cardiol. 39(10): 615–620. doi:10.1002/clc.22578. PMID:27511965.
Thollon, C., Cambarrat, C., Vian, J., Prost, J.F., Peglion, J.L., and Vilaine, J.P.
1994. Electrophysiological effects of S 16257, a novel sino-atrial node
modulator, on rabbit and guinea-pig cardiac preparations: comparison
with UL-FS 49. Br. J. Pharmacol. 112(1): 37–42. doi:10.1111/j.1476-5381.1994.
tb13025.x. PMID:8032660.
Tomaselli, G.F., and Marban, E. 1999. Electrophysiological remodeling in hy-
pertrophy and heart failure. Cardiovasc. Res. 42(2): 270–283. doi:10.1016/
S0008-6363(99)00017-6. PMID:10533566.
Tomaselli, G.F., and Zipes, D.P. 2004. What causes sudden death in heart
failure? Circ. Res. 95(8): 754–763. doi:10.1161/01.RES.0000145047.14691.db.
PMID:15486322.
Tomaselli, G.F., Beuckelmann, D.J., Calkins, H.G., Berger, R.D., Kessler, P.D.,
Lawrence, J.H., et al. 1994. Sudden cardiac death in heart failure. The role
of abnormal repolarization. Circulation, 90(5): 2534–2539. doi:10.1161/01.
CIR.90.5.2534. PMID:7955213.
Trenor, B., Cardona, K., Gomez, J.F., Rajamani, S., Ferrero, J.M., Jr., Belardinelli, L.,
et al. 2012. Simulation and mechanistic investigation of the arrhythmogenic
role of the late sodium current in human heart failure. PLoS One, 7(3):
e32659. doi:10.1371/journal.pone.0032659. PMID:22427860.
Tsuji, Y., Opthof, T., Kamiya, K., Yasui, K., Liu, W., Lu, Z., et al. 2000. Pacing-
induced heart failure causes a reduction of delayed rectifier potassium
currents along with decreases in calcium and transient outward currents
in rabbit ventricle. Cardiovasc. Res. 48(2): 300–309. doi:10.1016/S0008-
6363(00)00180-2. PMID:11054476.
Tsutsui, H., Momomura, S., Yamashina, A., Ogawa, H., Shimokawa, H.,
Kihara, Y., et al. 2016. Heart rate control with if inhibitor, ivabradine, in
Japanese patients with chronic heart failure: a randomized, double-blind,
placebo-controlled Phase II study. Circ. J. 80(3): 668–676. doi:10.1253/circj.
CJ-15-1112. PMID:26763489.
Verkerk, A.O., Wilders, R., Coronel, R., Ravesloot, J.H., and Verheijck, E.E.
2003. Ionic remodeling of sinoatrial node cells by heart failure. Circulation,
108(6): 760–766. doi:10.1161/01.CIR.0000083719.51661.B9. PMID:12885752.
Villacorta, A.S., Villacorta, H., Caldas, J.A., Precht, B.C., Porto, P.B., Rodrigues, L.U.,
et al. 2019. Effects of heart rate reduction with either pyridostigmine or
ivabradine in patients with heart failure: a randomized, double-blind study.
J. Cardiovasc. Pharmacol. Ther. 24(2): 139–145. doi:10.1177/1074248418799364.
PMID:30198318.
Volterrani, M., Cice, G., Caminiti, G., Vitale, C., D’Isa, S., Perrone Filardi, P.,
et al. 2011. Effect of Carvedilol, Ivabradine or their combination on exer-
cise capacity in patients with heart failure (the CARVIVA HF trial). Int. J.
Cardiol. 151(2): 218–224. doi:10.1016/j.ijcard.2011.06.098. PMID:21764469.
Wang, Y.L., Guo, J.H., Li, X.B., Ren, X.J., Han, Z.H., and Chen, F. 2010. Electro-
physiological characterization and efficacy of radiofrequency ablation of
focal atrial tachycardia originating from the left atrial appendage.
Zhonghua Xin Xue Guan Bing Za Zhi, 38(6): 49 3–496. PMID:21033128.
Wells, G.A., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., and
Tugwell, P. 2013. The Newcastle-Ottawa Scale (NOS) for assessing the qual-
ity of nonrandomised studies in meta-analyses. Ottawa Hospital Research
Institute, Ottawa, Ont.
Workman, A.J., Kane, K.A., and Rankin, A.C. 2003. Characterisation of the
Na, K pump current in atrial cells from patients with and without
chronic atrial fibrillation. Cardiovasc. Res. 59(3): 593–602. doi:10.1016/
S0008-6363(03)00466-8. PMID:14499860.
Yamamoto, K. 2015. b-blocker therapy in heart failure with preserved ejec-
tion fraction: Importance of dose and duration. J. Cardiol. 66(3): 189–194.
doi:10.1016/j.jjcc.2015.02.004. PMID:25881728.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E, Jr., Drazner, M.H.,
et al. 2013. ACCF/AHA guideline for the management of heart failure: a
report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62(16):
e147–239. doi:10.1016/j.jacc.2013.05.019. PMID:23747642.
Zaza, A., and Lombardi, F. 2001. Autonomic indexes based on the analysis of
heart rate variability: a view from the sinus node. Cardiovasc. Res. 50(3):
434–442. doi:10.1016/S0008-6363(01)00240-1. PMID:11376619.
Zicha, S., Fernandezvelasco, M., Lonardo, G., Lheureux, N., and Nattel, S.
2005. Sinus node dysfunction and hyperpolarization-activated (HCN)
channel subunit remodeling in a canine heart failure model. Cardiovasc
Res. 66(3): 472–481. doi:10.1016/j.cardiores.2005.02.011. PMID:15914112.
Zile, M.R., and Gaasch, W.H. 2011. Abnormal calcium homeostasis: one
mechanism in diastolic heart failure. J. Am. Coll. Cardiol. 58(2): 155–157.
doi:10.1016/j.jacc.2010.10.068. PMID:21718912.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
16 Can. J. Physiol. Pharmacol. Vol. 00, 0000
Published by Canadian Science Publishing
C
an
. J
. P
hy
si
ol
. P
ha
rm
ac
ol
. D
ow
nl
oa
de
d 
fr
om
 c
dn
sc
ie
nc
ep
ub
.c
om
 b
y 
84
.0
.4
7.
17
9 
on
 1
0/
17
/2
1
Fo
r 
pe
rs
on
al
 u
se
 o
nl
y.
 
